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Background: Subclinical hyperthyroidism (SHyper) has been associated with increased risk 
for hip and other fractures, but the linking mechanisms remain unclear.  
Objective: To investigate the association between subclinical thyroid dysfunction and bone 
loss. 
Methods: Individual participant data analysis after a systematic literature search in 
MEDLINE/EMBASE (1946-2016). Two reviewers independently screened and selected 
prospective cohorts providing baseline thyroid status and serial bone mineral density (BMD) 
measurements. We classified thyroid status as euthyroidism (thyroid-stimulating hormone 
[TSH] 0·45-4·49mIU/l), SHyper (TSH<0.45mIU/l) and subclinical hypothyroidism (SHypo, 
TSH≥4·50-19·99mIU/l) both with normal free thyroxine levels. Our primary outcome was 
annualized percentage BMD change (%ΔBMD) from serial dual x-ray absorptiometry scans of 
the femoral neck, total hip and lumbar spine, obtained from multivariable regression in a 
random-effects two-step approach. 
Results: Among 5,458 individuals (median age 72 years, 49·1% women) from 6 prospective 
cohorts, 451 (8·3%) had SHypo and 284 (5·2%) had SHyper. During 36,569 person-years of 
follow-up, those with SHyper had a greater annual bone loss at the femoral neck vs. 
euthyroidism: %ΔBMD=-0·18 (95%CI:-0·34,-0·02; I2=0%), with a non-statistically significant 
pattern at the total hip: %ΔBMD=-0·14 (95%CI:-0·38,0·10; I2=53%), but not at the lumbar 
spine: %ΔBMD=0·03 (95%CI:-0·30,0·36; I2=25%). Especially participants with 
TSH<0·10mIU/l showed an increased bone loss in the femoral neck (%ΔBMD=-0·59;[95%CI:-
0·99,-0·19]) and total hip region (%ΔBMD=-0·46 [95%CI:-1·05,-0·13]). In contrast, SHypo 
was not associated with bone loss at any site.  
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Conclusion: Among adults, SHyper was associated with increased femoral neck bone loss, 




Overt hyperthyroidism is a known risk factor for decreased bone mineral density (BMD) and 
fractures (1-3) whereas overt hypothyroidism is not, except during thyroxine 
overreplacement.(4) Compared to overt thyroid disease, subclinical thyroid dysfunction 
(SCTD) is a more common phenomenon, with a prevalence reaching 10% for subclinical 
hypothyroidism (SHypo) in the elderly (5) and 3·2% for subclinical hyperthyroidism 
(SHyper).(6) 
Among 70,298 individual participant data (IPD) from prospective cohort studies, we found that 
SHyper (but not SHypo) was associated with an increased risk up to 36% of fractures compared 
to euthyroidism.(7) 
Yet the underlying pathophysiologic mechanism remains unclear. Increased bone loss may 
mediate this association, and is best assessed with serial bone mineral density measurements to 
assess bone health and evaluate the future risk for osteoporotic fractures.(8, 9) However, data 
on the association between SCTD and bone loss are limited to one prospective cohort study 
conducted only in men.(10) To investigate the influence of SCTD on bone loss, a potential 
mediator in its association with fracture risk, we conducted a pooled IPD analysis from all 
population-based prospective cohort studies with baseline thyroid status and serial BMD 
assessments. 
Methods 
Search Strategy and Selection Criteria  
We report this IPD analysis according to the PRISMA-IPD statement (11) and published the 
study protocol online in the International prospective register of meta-analyses (PROSPERO 
CRD42015019814).(12). We conducted a systematic literature search in EMBASE and 
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Medline from inception until September, 5th, 2016 without language restrictions, and searched 
bibliographies of key articles in the field. We included IPD from prospective cohorts with 
available baseline thyroid status and serial BMD measurements. We excluded studies assessing 
individuals with overt thyroid dysfunction only, or limited to participants pre-treated for either 
thyroid or bone diseases. Two physicians (DS, CEA) independently assessed each study’s 
eligibility (title and abstract screen: Cohen’s kappa coefficient [κ]=0·80; full-text search: 
κ=1·00), potential risks of bias, and study quality using the Newcastle-Ottawa Quality 
Assessment Scale.(13) Remaining uncertainties were solved with a third author (NR). 
Furthermore, we included unpublished IPD from the Thyroid Studies Collaboration,(7) an 
international network of high-quality prospective cohort studies. In case of unclear data issues 
(e.g. unreasonable outliers), we contacted the designated cohort contact persons. 
 
Thyroid Status 
All cohorts measured TSH using third-generation assays, whereas fT4 assay kits varied across 
studies. Similar to previous IPD analyses,(7, 14, 15) we used uniform TSH cutoff levels based 
on an expert consensus meeting of the Thyroid Studies Collaboration, expert reviews,(16, 17) 
and cohort-specific cut-offs for fT4 reference ranges (Appendix Table 1) for a better 
comparability. We defined euthyroidism as TSH 0.45-4.49mIU/l, SHypo as TSH between 4.50-
19.99mIU/l with fT4 within reference range, SHyper as TSH <0.45mIU/l with fT4 within 
reference range. We excluded individuals with overt hypothyroidism (n=124) and 





Assessment of Bone- and Thyroid-Altering Medication 
We collected data on anti-osteoporotic medication(18) and glucocorticoids(19) in all cohorts at 
baseline and during follow-up. Bone-altering medication comprised: bisphosphonates, 
calcitonin, teriparatide, proton pump inhibitors, selective estrogen receptor modulators, oral 
corticosteroids, thiazides, postmenopausal hormone therapy, contraceptives, androgens, anti-
androgens, and fluorides. Similarly, we collected all available data on thyroid-altering 
medication: thyroxine, anti-thyroid drugs, lithium, and amiodarone. 
 
Annualized Percentage Change in Bone Mineral Density (%ΔBMD) 
Our primary outcome was the annualized percentage change between baseline and the last 
available follow-up measurements (%ΔBMD) at the femoral neck, total hip, and lumbar spine, 
in order to standardize BMD measurements across different cohorts, devices and follow-up 
durations, as in former study-level meta-analyses.(20, 21) 
All BMD measurements were obtained from gold-standard dual x-ray absorptiometry (DXA, 
Appendix Table 1). The rationale for total hip, femoral neck, and lumbar spine as reference 
body sites was their high relevance to the risk assessment of major osteoporotic fractures.(22) 
To increase the accuracy and reproducibility for each body site, all cohorts implemented a strict 
quality control with cross-calibration using standardized phantoms to avoid inter-device 
variability and longitudinal shifts and drifts (Appendix Table 2). 
In a previous publication, we observed an increased risk of hip fractures in participants with 
SHyper.(7) In the current work, we also examined whether this could be explained by the 
mediating effect of increased bone loss in this region. For this secondary analysis, every cohort 
provided us with both data on incident fractures and %ΔBMD. The definitions of fracture 




Following recommendations for IPD analyses (23, 24) and previous studies,(7, 14) we used a 
random-effects two-step approach, first analyzing associations between thyroid status and 
%ΔBMD for each cohort using linear multivariable regression models controlling for age, sex, 
body mass index (BMI),(25) diabetes mellitus,(25) smoking,(26) and menopausal status.(27) 
Data were complete for age and sex, with rare missing data for BMI (0·2%), smoking (0·3%), 
menopausal status (0·3%), and diabetes mellitus (<0·01%). This approach yielded adjusted 
differences in %ΔBMD between euthyroid individuals and those with SHyper or SHypo, and 
respective standard errors. In a second step, we calculated pooled estimates with 95%CI using 
inverse-variance random-effects models,(28) and assessed the heterogeneity across cohorts by 
means of I2 statistic.(29). Additional information is detailed in the Appendix. 
Results 
Out of 1,558 articles identified in our literature search and through contact with experts, six 
cohort studies met all inclusion criteria (Appendix Figure 1).(10) Two other cohorts were 
potentially eligible, but not included because of different BMD measurement techniques and 
devices.(30, 31) The final sample for our primary outcome comprised 5,458 individuals 
(median age 72 years, 49·1% female participants) with a median follow-up of 6·7 years and 
total observation of 36,569 patient-years (Table 1). 4,723 (86·5%) participants were euthyroid, 
451 (8·3%) had SHypo, and 284 (5·2%) had SHyper, including 230 (4·2%) with low but not 
suppressed TSH (0·10-0·44 mIU/l) and 54 (1·0%) with suppressed TSH (<0·10mIU/l). 
According to the modified Newcastle-Ottawa Quality Assessment Scale,(13) study quality was 
good to excellent with three studies achieving the full score of seven,(32-34) and three studies 
with six points (Appendix Table 2).(10, 35, 36) 
In euthyroid individuals, femoral neck BMD decreased 0·59% per year (95%CI:0·54, 0·63), 
total hip BMD decreased 0·55% per year (95%CI:0·49, 0·61), while spine BMD increased 
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0·32% per year (95%CI:-0·21, 0·84) in unadjusted models. In multivariable regression models, 
SHyper was associated with an increased bone loss at the femoral neck compared to 
euthyroidism: %ΔBMD=-0·18 (95%CI:-0·34, -0·02; I2=0·0%, Appendix Figure 2), with a non-
statistically significant pattern for total hip: %ΔBMD=-0·14 (95%CI:-0·38, 0·10, I2=52·7%), 
but not for lumbar spine: %ΔBMD=0·03 (95%CI:-0·30, 0·36; I2=24·8%) (Table 2). Among 
participants with SHyper and TSH <0·10 mUI/l, bone loss notably increased at the femoral 
neck [%ΔBMD=-0·59 (95%CI:-0·99,-0·19, I2=0·0%)], with a similar pattern at the total hip 
[%ΔBMD=-0·46 (95%CI:-1·05,0·13, I2=59·5%)] compared to euthyroidism. In contrast, 
SHypo was not associated with increased bone loss at any body site (Appendix Table 3).  An 
analysis stratifying for cohort-specific fT4 quartiles resulted in a significantly increased hip 
bone loss in the highest vs. lowest fT4 quartile for both femoral neck %ΔBMD=-0·18 (95%CI:-
0·29, -0·06, p<0·01) and total hip %ΔBMD=-0·20 (95%CI:-0·27, -0·12, p=0·02, Figure 1). In 
SHyper, bone loss was significantly increased for both men and women at the femoral neck 
(%ΔBMD=-0·33 [95%CI:-0·66, -0·01] vs. %ΔBMD=-0·14 [95%CI:-0·24, -0·05]) compared 
to euthyroidism, however without effect modification by gender (p for interaction 0·58), but 
not total hip (%ΔBMD=-0·38 [95%CI:-0·80, 0·03] vs. %ΔBMD=-0·05 [95%CI:-0·25, 0·14], 
p for interaction=0·43). There was a pattern for a larger bone decrease at the femoral neck 
among participants with SHyper ≥75 vs. < 75 years (%ΔBMD=-0·34 [95%CI:-0·52, -0·16] vs. 
%ΔBMD=-0·13 [95%CI:-0·22, -0·04], p for interaction=0·09), but not at the total hip 
(%ΔBMD=-0·28 [95%CI:-0·69, 0·12] vs. %ΔBMD=-0·15 [95%CI:-0·33, 0·04], p for 
interaction=0·77).  
Most sensitivity analyses yielded similar results (Table 2), whereas exclusion of both thyroid- 
and bone-altering drug users at any time showed a greater bone loss in SHyper at the femoral 
neck and a comparable pattern for total hip, without significant changes for lumbar spine. When 
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excluding studies with >20% missing follow-up BMD, bone loss was significantly increased in 
SHyper at both hip measurement sites. 
The adjusted HR for fractures associated with SHyper was 1·47 (95%CI:0·74, 2·91; p=0·27) 
for hip, 1·19 (95%CI:0·69, 2·03; p=0·53) for any, and 0·95 (95%CI:0·58, 1·57; p=0·85) for 
non-spine fractures. Compared to our previous publication,(7) confidence intervals were larger 
due to the smaller number of individuals with both fracture assessment and serial BMD scans 
(N=5,458 vs. N=70,298). Additional adjustment for baseline BMD and %ΔBMD in the total 
hip region yielded lower risk estimates, particularly for hip fractures (HR=1·28; 95%CI:0·64, 
2·54; p=0·49). Additionally, there was no significant effect modification by thyroid status 
(SHyper vs. euthyroidism) in the association between %ΔBMD in the hip region and the risk 
for hip, non-spine and any fractures (Appendix Table 4). 
Discussion 
In our IPD analysis of 5,458 individuals from six population-based prospective cohorts, SHyper 
was associated with a moderately increased annualized bone loss at the femoral neck with a 
similar, non-significant trend for total hip, but not for lumbar spine, which may be influenced 
by the development of degenerative arthritis and vascular calcification. Bone loss at the femoral 
neck and total hip was largest among individuals with TSH levels <0·10 mUI/l showing 
approximately a double to 3-fold annualized rate of hip bone loss. Moreover, participants in the 
highest fT4 quartile had a more pronounced hip bone loss than participants in the lowest fT4 
quartile. Conversely, SHypo was not associated with increased bone loss compared to euthyroid 
controls. 
Bone loss at the femoral neck and, to a lesser extent, at total hip, was even greater after 
excluding individuals on bone metabolism and/or thyroid function-altering medication at any 
time. These results suggest increased hip bone loss especially in endogenous forms of SHyper, 
and are compatible with a recent study-level meta-analysis with 78% higher fracture risk in 
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endogenous and 25% higher in exogenous forms of SHyper vs euthyroidism. (37) A cross-
sectional study among 88 postmenopausal women reported significantly lower hip and lumbar 
spine BMD levels in endogenous, but not exogenous SHyper.(38) Longer exposure to decreased 
TSH levels in endogenous SHyper could be an explanation,(37, 39) as exogenous SHyper is 
usually quickly corrected with regular TSH monitoring. 
Although there was no evidence of interaction by age or sex on the association between SHyper 
and hip bone loss, point estimates for femoral neck/total hip %ΔBMD in SHyper were lower in 
men than in women. These results are compatible with our previous publication showing a 
higher HR for hip fractures in men than in women with SHyper compared to euthyroid controls 
([HR=1·92, 95%CI:1·26, 2·94] vs. [HR=1·29, 95%CI:1·08, 1·55], p for interaction 0·09).(7) 
Our study found a potential mediating effect of hip bone loss in the association between SHyper 
and increased risk for hip fractures, as shown by the decreased HRs after additional adjustment 
for %ΔBMD and baseline BMD at the total hip. However, confidence intervals were large and 
the association was not statistically significant , as power was limited by the relatively low 
number of hip fractures (265 in the present analysis compared to 2,975 in our previous 
article).(7) Additionally, we found no clear interaction of thyroid status (SHyper vs 
euthyroidism) in the association between %ΔBMD in the hip region and fracture risk. 
Therefore, there may be additional mediators such as bone turnover and neuromuscular function 
in the association between SHyper and fracture risk. SHyper has been associated with reduced 
muscle strength,(40) increased frailty,(41) and an increased cardiovascular morbidity(15) in 
previous prospective cohorts, which all may result in an increased risk for falls and subsequent 
low-traumatic fractures.  
Our study has the following strengths. It is the first analysis on the association between SCTD 
and bone loss including a large proportion of IPD from six prospective population-based cohort 
studies from five different countries with a balanced gender distribution. Compared to study-
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level meta-analyses, an IPD analysis increases the power and accuracy of aggregated evidence 
by providing highly standardized and confounder-adjusted results from different cohort studies 
and reliable data on subgroups without ecological fallacy.(23) Although causality and the role 
of a drug intervention cannot be established in a cohort study, these data represent the best 
available evidence, as there is no published or ongoing randomized controlled trial on this topic 
to our knowledge. We could exclude individuals on thyroid- and bone-altering medication at 
any time point in our main and sensitivity analyses reducing the possibility of treatment bias. 
However, our study has some limitations. First, we could not assess the association between 
persistent SCTD and bone loss, as serial thyroid hormone measurements were obtained only in 
one cohort. SHyper has an annual spontaneous progression rate of only 1-2%,(16) and SHypo 
of 3-4%(6) to overt thyroid disease. In a sensitivity analysis, we accounted for this issue 
excluding both bone- and thyroid-altering drug users at any time, which found an even faster 
bone loss at the femoral neck in SHyper. Second, the etiology of SHyper was not systematically 
assessed which precluded further subgroup analyses. Third, available information on drug 
treatment varied somewhat in detail and time span. However, missingness for thyroid- or bone-
altering drugs at baseline was negligible (thyroid replacement therapy [0·75%], anti-
osteoporotic agents [1·06%], oral corticosteroids [0·76%]). Fourth, our study population was 
older than the general population, which may reduce the generalizability of our results to 
younger individuals with SHyper. Fifth, only the OPUS(36) offered information on 
triiodothyronine (T3) levels, which made a uniform exclusion of participants with abnormal T3 
values impossible. Thus, some individuals suffering from T3-toxicosis or non-thyroidal illness 
may have been included in the subgroup of SHyper. Finally, although we observed a potential 
mediating effect of total hip %ΔBMD in the association between SHyper and hip fractures, this 




Hip bone loss was increased in individuals with SHyper, especially in those with TSH 
<0·10mIU/l, high-normal fT4 levels, and SHyper of potentially endogenous etiology, compared 
to euthyroidism. These results suggest that individuals with SHyper may be exposed to a greater 
osteoporosis risk due to accelerated hip bone loss. Although bone loss may not solely be 
responsible for the increased fracture risk, SHyper would represent a treatable risk factor. 
Acknowledgements 
 Financial Support 
This work was supported by grants from the Swiss National Science Foundation (SNSF 320030-150025 
and 320030-172676 to Prof. Rodondi). Dr. Collet’s research is supported by grants from the Swiss 
National Science Foundation (P3SMP3-155318, PZ00P3-167826). Cardiovascular Health Study 
(CHS): This research was supported by contracts HHSN268201200036C, HHSN268200800007C, 
N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, 
N01HC85086, and grant U01HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), 
with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). 
Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full 
list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. Health, Aging 
and Body Composition (Health ABC) study: The Health, Aging, and Body Composition study is 
supported by contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 from the National 
Institute on Aging; grant R01-AG028050 from the National Institute on Aging; grant R01-NR012459 
from the National Institute of Nursing Research; and by the Intramural Research Program of the National 
Institutes of Health, National Institute on Aging. Osteoporotic Fractures in Men (MrOS) Study: The 
Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The 
following institutes provide support: the National Institute on Aging (NIA), the National Institute of 
Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing 
13 
 
Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant 
numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 
AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. Osteoporosis and Ultrasound 
Study (OPUS): supported by Sanofi-Aventis, Eli Lilly, Novartis, Pfizer, Proctor and Gamble 
Pharmaceuticals and Roche. Rotterdam Study: funded by Erasmus MC and Erasmus University, 
Rotterdam, the Netherlands; the Netherlands Organisation for Scientific Research (NWO); the 
Netherlands Organisation for the Health Research and Development (ZonMw); the Research Institute 
for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Dutch Ministry 
for Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. 
Sheffield Study: funded by Arthritis Research United Kingdom 
Contribution 
Study design: Segna, Bauer, Rodondi; statistical analyses: Segna, Bauer, Rodondi, Collet, da Costa, 
Feller, Bischoff-Ferrari, Fischer; literature search: Segna, Aubert; manuscript writing: Segna, Rodondi, 
Bauer, Feller; data collection and preparation: Segna, Rodondi, Bauer, Eastell, Williams, Peeters, 
Uitterlinden, Rivadeneira Ramírez, Gogakos, Naylor, Cauley; critical review of the manuscript: 
Schneider, Fink, Aubert, Collet, da Costa, Fischer, Peeters, Cappola, Blum, van Dorland, Robbins, 
Naylor, Eastell, Uitterlinden, Rivadeneira Ramírez, Gogakos, Gussekloo, Williams, Schwartz, Cauley, 
Aujesky, Bischoff-Ferrari. 
Conflict of interest 
Dr. Rodondi and Dr. Gussekloo report funding for a randomized controlled trial on subclinical 
hypothyroidism (TRUST trial) from the European Commission FP7-HEALTH-2011, Specific 
Programme “Cooperation” – Theme “Health” Investigator-driven clinical trials for therapeutic 
interventions in elderly populations (Proposal No: 278148-2). Dr. Peeters reports lecture and/or advisory 
board fees from Genzyme B.V., EISAI, IPSEN, and Goodlife Fertility; and grant support from Veracyte, 
all outside of the submitted work. Dr. Eastell reports grants and personal fees from Amgen, grants from 
Department of Health, grants from AstraZeneca, grants, personal fees and non-financial support from 
14 
 
Immunodiagnostic Systems, grants from ARUK/MRC Centre for Excellence in Musculoskeletal Ageing 
Research, grants from National Institute for Health Research, grants from MRC/AZ Mechanisms of 
Diseases Call, grants from MRC , grants and personal fees from Alexion, grants and other from National 
Osteoporosis Society, grants, personal fees and other from Roche, personal fees and other from Eli Lilly, 
other from European Calcified Tissue Society, other from IOF CSA, other from IBMS, other from 
ASBMR, personal fees from D-STAR, personal fees from GSK Nutrition,  outside the submitted work; 
Dr Robbins reports funding from NHLBI during the conduct of the study. Dr Collet reports grants from 
Swiss National Science foundation during the conduct of the study. 
 
References 
1. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk 
factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N 
Engl J Med. 1995;332(12):767-73. Epub 1995/03/23. doi: 10.1056/nejm199503233321202. 
PubMed PMID: 7862179. 
2. El Hadidy el HM, Ghonaim M, El Gawad S, El Atta MA. Impact of severity, duration, 
and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. 
BMC Endocr Disord. 2011;11:15. Epub 2011/08/09. doi: 10.1186/1472-6823-11-15. PubMed 
PMID: 21819612; PubMed Central PMCID: PMCPMC3176471. 
3. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk--a 
meta-analysis. Thyroid. 2003;13(6):585-93. Epub 2003/08/22. doi: 
10.1089/105072503322238854. PubMed PMID: 12930603. 
4. Abrahamsen B, Jorgensen HL, Laulund AS, Nybo M, Bauer DC, Brix TH, et al. The 
excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative 
hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved 
cohort analysis. J Bone Miner Res. 2015;30(5):898-905. Epub 2014/11/29. doi: 
10.1002/jbmr.2416. PubMed PMID: 25431028. 
5. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et 
al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): 
National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 
2002;87(2):489-99. Epub 2002/02/12. doi: 10.1210/jcem.87.2.8182. PubMed PMID: 
11836274. 
6. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. 
Endocr Rev. 2008;29(1):76-131. Epub 2007/11/10. doi: 10.1210/er.2006-0043. PubMed 
PMID: 17991805. 
7. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Subclinical 
thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055-65. Epub 
2015/05/27. doi: 10.1001/jama.2015.5161. PubMed PMID: 26010634; PubMed Central 
PMCID: PMCPMC4729304. 
8. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive 
Value of BMD for Hip and Other Fractures. Journal of Bone and Mineral Research. 
2005;20(7):1185-94. doi: 10.1359/jbmr.050304. 
15 
 
9. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone 
density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures 
Research Group. Lancet. 1993;341(8837):72-5. Epub 1993/01/09. PubMed PMID: 8093403. 
10. Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, Zmuda JM, et al. A 
prospective study of thyroid function, bone loss, and fractures in older men: The MrOS study. 
J Bone Miner Res. 2013;28(3):472-9. 
11. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred 
Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the 
PRISMA-IPD Statement. Jama. 2015;313(16):1657-65. Epub 2015/04/29. doi: 
10.1001/jama.2015.3656. PubMed PMID: 25919529. 
12. Segna D. The relationship between subclinical thyroid dysfunction and bone mineral 
density: an individual participant data analysis. 
http://wwwcrdyorkacuk/PROSPERO/display_recordasp?ID=CRD42015019814. 2016. 
13. Wells GA SB, O'Connell D,Peterson J, Welch V , Losos M, Tugwell P. The 
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-
analyses. http://wwwohrica/programs/clinical_epidemiology/oxfordasp. 
14. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. 
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. Jama. 
2010;304(12):1365-74. 
15. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. 
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern 
Med. 2012;172(10):799-809. Epub 2012/04/25. doi: 10.1001/archinternmed.2012.402. 
PubMed PMID: 22529182; PubMed Central PMCID: PMCPmc3872478. 
16. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid 
disease: scientific review and guidelines for diagnosis and management. Jama. 
2004;291(2):228-38. 
17. Helfand M. Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A 
Summary of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal 
Medicine. 2004;140(2):128-41. doi: 10.7326/0003-4819-140-2-200401200-00015. 
18. Reid IR. Short-term and long-term effects of osteoporosis therapies. Nature reviews 
Endocrinology. 2015;11(7):418-28. Epub 2015/05/13. doi: 10.1038/nrendo.2015.71. PubMed 
PMID: 25963272. 
19. Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, 
management, and future perspectives. The lancet Diabetes & endocrinology. 2013;1(1):59-
70. Epub 2014/03/14. doi: 10.1016/s2213-8587(13)70045-7. PubMed PMID: 24622268. 
20. Li D, Hitchcock CL, Barr SI, Yu T, Prior JC. Negative spinal bone mineral density 
changes and subclinical ovulatory disturbances--prospective data in healthy premenopausal 
women with regular menstrual cycles. Epidemiol Rev. 2014;36:137-47. Epub 2013/11/28. 
doi: 10.1093/epirev/mxt012. PubMed PMID: 24275546. 
21. Chang KV, Hung CY, Chen WS, Lai MS, Chien KL, Han DS. Effectiveness of 
bisphosphonate analogues and functional electrical stimulation on attenuating post-injury 
osteoporosis in spinal cord injury patients- a systematic review and meta-analysis. PLoS 
One. 2013;8(11):e81124. Epub 2013/11/28. doi: 10.1371/journal.pone.0081124. PubMed 
PMID: 24278386; PubMed Central PMCID: PMCPMC3838359. 
22. Leslie WD, Brennan-Olsen SL, Morin SN, Lix LM. Fracture prediction from repeat 
BMD measurements in clinical practice. Osteoporosis international : a journal established as 
result of cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA. 2015. Epub 2015/08/06. doi: 10.1007/s00198-015-
3259-y. PubMed PMID: 26243362. 
23. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: 
rationale, conduct, and reporting. Bmj. 2010;340:c221. Epub 2010/02/09. doi: 
10.1136/bmj.c221. PubMed PMID: 20139215. 
24. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-
analysis of individual patient data from randomized trials: a review of methods used in 




25. Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T, et al. Clinical 
review. Risk factors for low bone mass-related fractures in men: a systematic review and 
meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1861-70. Epub 2012/04/03. doi: 
10.1210/jc.2011-3058. PubMed PMID: 22466344. 
26. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone 
mineral density. Calcified tissue international. 2001;68(5):259-70. Epub 2001/10/31. PubMed 
PMID: 11683532. 
27. Cauley JA. Bone health after menopause. Current opinion in endocrinology, diabetes, 
and obesity. 2015;22(6):490-4. Epub 2015/10/30. doi: 10.1097/med.0000000000000204. 
PubMed PMID: 26512774. 
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 
1986;7(3):177-88. Epub 1986/09/01. PubMed PMID: 3802833. 
29. da Costa BR, Juni P. Systematic reviews and meta-analyses of randomized trials: 
principles and pitfalls. European heart journal. 2014;35(47):3336-45. Epub 2014/11/25. doi: 
10.1093/eurheartj/ehu424. PubMed PMID: 25416325. 
30. Svare A, Nilsen TI, Asvold BO, Forsmo S, Schei B, Bjoro T, et al. Does thyroid 
function influence fracture risk? Prospective data from the HUNT2 study, Norway. Eur J 
Endocrinol. 2013;169(6):845-52. Epub 2013/09/14. doi: 10.1530/eje-13-0546. PubMed 
PMID: 24031093. 
31. Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, et al. Thyroid 
status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging 
in the Chianti Area Study. J Am Geriatr Soc. 2013;61(6):868-74. Epub 2013/05/08. doi: 
10.1111/jgs.12267. PubMed PMID: 23647402; PubMed Central PMCID: PMCPmc3686888. 
32. Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, et al. 
The effects of adiponectin and leptin on changes in bone mineral density. Osteoporosis 
international : a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 
2012;23(6):1699-710. Epub 2011/08/31. doi: 10.1007/s00198-011-1768-x. PubMed PMID: 
21877199; PubMed Central PMCID: PMCPMC3536828. 
33. Finigan J, Greenfield DM, Blumsohn A, Hannon RA, Peel NF, Jiang G, et al. Risk 
factors for vertebral and nonvertebral fracture over 10 years: a population-based study in 
women. J Bone Miner Res. 2008;23(1):75-85. Epub 2007/09/06. doi: 10.1359/jbmr.070814. 
PubMed PMID: 17784843. 
34. van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP, 
et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on 
bone: the Rotterdam Study. Clin Endocrinol. 2008;68(2):175-81. 
35. Garin MC, Arnold AM, Lee JS, Robbins J, Cappola AR. Subclinical thyroid 
dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular 
health study. J Clin Endocrinol Metab. 2014;99(8):2657-64. 
36. Murphy E, Gluer CC, Reid DM, Felsenberg D, Roux C, Eastell R, et al. Thyroid 
function within the upper normal range is associated with reduced bone mineral density and 
an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J 
Clin Endocrinol Metab. 2010;95(7):3173-81. Epub 2010/04/23. doi: 10.1210/jc.2009-2630. 
PubMed PMID: 20410228. 
37. Yan Z, Huang H, Li J, Wang J. Relationship between subclinical thyroid dysfunction 
and the risk of fracture: a meta-analysis of prospective cohort studies. Osteoporosis 
international : a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 
2016;27(1):115-25. Epub 2015/08/01. doi: 10.1007/s00198-015-3221-z. PubMed PMID: 
26223189. 
38. Belaya ZE, Melnichenko GA, Rozhinskaya LY, Fadeev VV, Alekseeva TM, Dorofeeva 
OK, et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in 
postmenopausal women. Hormones (Athens, Greece). 2007;6(1):62-70. Epub 2007/02/28. 
PubMed PMID: 17324919. 
17 
 
39. Biondi B. Natural history, diagnosis and management of subclinical thyroid 
dysfunction. Best practice & research Clinical endocrinology & metabolism. 2012;26(4):431-
46. Epub 2012/08/07. doi: 10.1016/j.beem.2011.12.004. PubMed PMID: 22863386. 
40. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS. The impact of overt 
and subclinical hyperthyroidism on skeletal muscle. Thyroid. 2006;16(4):375-80. Epub 
2006/05/02. doi: 10.1089/thy.2006.16.375. PubMed PMID: 16646684. 
41. Virgini VS, Rodondi N, Cawthon PM, Harrison SL, Hoffman AR, Orwoll ES, et al. 
Subclinical Thyroid Dysfunction and Frailty Among Older Men. J Clin Endocrinol Metab. 
2015;100(12):4524-32. Epub 2015/10/27. doi: 10.1210/jc.2015-3191. PubMed PMID: 
26495751; PubMed Central PMCID: PMCPmc4667157. 
42. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, et al. Design 
and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large 
observational study of the determinants of fracture in older men. Contemp Clin Trials. 
2005;26(5):569-85. Epub 2005/08/09. doi: 10.1016/j.cct.2005.05.006. PubMed PMID: 
16084776. 
Correspondence to:  
Prof. Nicolas Rodondi, MD, MAS, Head of Ambulatory Care, Department of General Internal 
Medicine, University of Bern, Bern University Hospital, Freiburgstrasse 4, 3010 Bern, 
Switzerland. Email: nicolas.rodondi@insel.ch. Tel: + 41 (31) 632 41 63. Fax: +41 (31) 632 88 
85 
Backup contact: 
Daniel Segna, MD, Department of General Internal Medicine, Bern University Hospital, 
Bern, Switzerland. Email: daniel.segna@insel.ch 
18 
 
Table 1: Baseline Characteristics of Included Cohort Studies 
General  
Follow-up for                                                       
Bone Mineral Density 






N               
























CDA aged ≥65y 
with Medicare 
eligibility in 2 US 
communities § 
425 
75·0         
(73·0-78·0) 
229    
(53·9%)  
1994-1995 




17       
(4·0%) 











CDA aged 70-79y 
with Medicare 
eligibility in 2 US 
communities 
1,772 
74·0        
(72·0-77·0) 
709    
(40·0%)  
1997-1998 



















CDMs aged ≥ 65y 
in 6 US clinical 
centers 
910 
72·0        
(68·0-76·0) 
0              
(0%)  
2000-2002 




11       
(1·2%) 
77   
(8·5%) 
 















63·6        
(39·5-70·4)        
665      
(100%)  
1999-2001 




102    
(15·3%) 
4     
(0·6%) 
 








Adults aged 55y+, 
Netherlands 
1,531 
68·1         
(62·6-73·9) 
924     
(60·4%)  
1990-1993 
7·0             
(2·9-11·1) 
10,717 
 101     
(6·6%) 
84    
(5·5%) 
 









85y, Sheffield, UK 
155 
63·5        
(57·7-68·8) 
155     
(100%)  
1990-1991 
10·0           
(5·1-10·0) 
1,550 





0     
(0·0%) 
9    
(5·8%) 
23                                  
(14·8%) 
Overall 6 cohorts 5,458 
72            
(67·0-76·0) 
2,682   
(49·1%) 
 1990-2001 
6·7             
(4·8-8·9) 
36,569 















Values given in absolute numbers and percentages for participants with serial dual-x-ray-absorptiometry (DXA) scans. For medication, percentage is related either to total number at baseline or follow-up, as 
appropriate. Abbreviations:  BMD: bone mineral density at any site of interest (femoral neck, total hip, lumbar spine). CA: California; CDA: community-dwelling adults; CDM: community-dwelling men; IQR: 
interquartile range; MD: Maryland; NC: North Carolina; PA: Pennsylvania; UK: United Kingdom; US: United States; y: years.  
Baseline characteristics for main analysis after exclusion of participants with one, or a combination of, bone-altering medication at baseline: hormone replacement therapy (n=878), anti-osteoporotic treatment (n=226, 
including bisphosphonates, calcitonin, teriparatide, selective estrogen receptor modulators, fluoride), proton pump inhibitors (n=177), oral corticosteroids (n=78), contraceptives (n=28), androgens (n=8), anti-androgens 
(n=2),   
* Thyroid-altering medication includes thyroid hormone replacement therapy and anti-thyroid drugs. OPUS and Sheffield Study did not record anti-thyroid drugs. Additional thyroid-altering drugs vary across studies 
and are considered in our main analysis  
† Anti-osteoporotic medication includes: bisphosphonates, calcitonin parathyroid hormone, selective estrogen receptor modulators, fluoride substitution. Additional bone-altering agents vary across studies and are 
considered in our main analysis.  
‡ Different follow-up durations for BMD across studies and participants, therefore individual information provided for each patient. 
§ Baseline and follow-up DXA scans from the study site in Pittsburgh, PA  





Table 2: Sensitivity Analyses for the Multivariable-Adjusted* Association between Subclinical 
Hyperthyroidism and Annualized Change in Bone Mineral Density 
  
N SHyper/Euthyroidism %ΔBMD 95%CI I2 p  
Femoral Neck      
Main analysis: 
Exclusion of bone drug users at baseline 
283/4700 -0·18 -0·34; -0·02 0·0% 0·44 
and no history of osteoporosis, and/or previous, 
and/or incident fractures 
222/3517 -0·23 -0·45; <-0·01 23·2% 0·26 
Exclusion of bone drug users† at any time 234/3559 -0·18 -0·36; <-0·01 0·0% 0·48 
Exclusion of both thyroid‡- and bone-influencing 
drug users at any time 
184/3348 -0·36 -0·71; <-0·01 45·9% 0·10 
Exclusion of cohorts with >20% missing follow-up 
BMD § 
154/2968 -0·36 -0·63; -0·09 0·0% 0·56 
Inclusion of participants with TSH<0.10mIU/l only 54/4700 -0·59 -0·99; -0·19 0·0% 0·44 
Total Hip      
Main analysis:                                                      
Exclusion of bone drug users at baseline 
232/4122 -0·14 -0·38; 0·10 52·7% 0·06 
and no history of osteoporosis, and/or previous, 
and/or incident fractures 
181/3013 -0·17 -0·53; 0·19 74·5% <0·01 
Exclusion of bone drug users† at any time 184/3037 -0·16 -0·47; 0·15 60·8% 0·03 
Exclusion of both thyroid‡- and bone-influencing 
drug users at any time 
141/2844 -0·40 -0·96; 0·16 81·9% <0·01 
Exclusion of cohorts with >20% missing follow-up 
BMD § 
103/2389 -0·38 -0·65; -0·10 15·8% 0·31 
Inclusion of participants with TSH<0.10mIU/l only 42/4122 -0·46 -1·05; 0·13 59·5% 0·04 
Lumbar Spine      
Main analysis:                                                         
Exclusion of bone drug users at baseline 
163/2974 0·03 -0·30; 0·36 24.8% 0·26 
and no history of osteoporosis, and/or previous, 
and/or incident fractures 
121/1985 -0·06 -0·42; 0·29 19·5% 0·29 
Exclusion of bone drug users† at any time 128/2069 0·33 -0·35; 1·00 64·6% 0·04 
Exclusion of both thyroid‡- and bone-influencing 
drug users at any time 
101/1930 0·39 -0·47; 1·25 64·7% 0·04 
Exclusion of cohorts with >20% missing follow-up 
BMD § 
53/1619 0·36 -0·55; 1·28 62·5% 0·10 
Inclusion of participants with TSH<0.10mIU/l only 23/2974 0·44 -1·12; 0·24 0·0% 0·52 
      
 
Footnote:  Abbreviations: %ΔBMD: annualized percentage change in bone mineral density compared to euthyroid individuals, I2: I2 
statistics, 95%CI: 95% confidence intervals; N: number of participants; p = p for heterogeneity, SHyper: subclinical hyperthyroidism.  
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* Multivariable adjustment for age, sex, bone mass index, smoking and menopausal status, history of diabetes. Values presented as mean 
difference in annualized percentage change in BMD, as compared to euthyroid controls. 
† Bone-altering drug users with intake of either bisphosphonates, calcitonin, teriparatide, selective estrogen receptor modulators, oral 
corticosteroids, thiazide diuretics, androgens, anti-androgens, hormone replacement therapy or proton pump inhibitors.  
‡ Thyroid-altering drug users with intake of either thyroxine, antithyroid drugs, amiodarone, or lithium.  
§  Exclusion of the Cardiovascular Health Study (35), Osteoporotic Fractures in Men (MrOS) Study(42) and Osteoporosis and Ultrasound 
Study (OPUS)(36) for the sensitivity analysis of  %ΔBMD at the femoral neck and total hip. Additionally, no data available for %ΔBMD at 
the lumbar spine in Rotterdam Study.(34) 
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Figure 1: Annualized Percentage Change in Hip Bone Mineral Density Stratified by Cohort-Specific fT4 Quartiles 
 
Legend: Multivariable adjustment for age, sex, bone mass index, smoking and menopausal status, history of diabetes. Values presented as mean difference in annualized percentage change in BMD 
(%ΔBMD). 95%CI: 95% confidence intervals; fT4: free thyroxine; quartiles obtained from each cohort, p for difference in %ΔBMD between the highest and lowest fT4 quartile. 
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Appendix Table 1: Definition of Thyroid Status* and Measurement Techniques/Devices for Bone Mineral Density 
Study Subclinical hypothyroidism Subclinical hyperthyroidism 
Measurement 
technique 




TSH ≥4·5mIU/l & TSH 
<20mIU/l, normal fT4 0·7-
1·7ng/dl (9-22pmol/l) or 
missing fT4 (0/42, 0·0%) 
TSH <0·45mIU/l & normal fT4 
0·7-1·7ng/dl (9-22pmol/l) or 
missing fT4 (0/17, 0·0%)  
 
DXA Hologic QDR 2000 (Hologic, 
Bedford, MA, USA) 
Total hip, femoral 
neck 
Health ABC 
Study (32) † 
TSH ≥4·5mIU/l & TSH 
<20mIU/l, normal fT4 0·8-
1·8ng/dl (10-23pmol/l) or 
missing fT4 (0/228, 0·0%)  
TSH <0.45mIU/l & normal fT4 
0.8-1.8ng/dl (10-23pmol/l) or 
missing fT4 (0/49, 0·0%) 
 
DXA Hologic QDR 4500, (Hologic, 
Bedford, MA, USA) 
Total hip, femoral 







TSH ≥4·5mIU/l & TSH 
<20mIU/l, normal fT4 0·7-
1·85ng/dl (9-24pmol/l) or 
missing fT4 (0/77, 0·0%)  
TSH <0·45mIU/l & normal fT4 
0·7-1·85ng/dl (9-24pmol/l) or 
missing fT4 (0/11, 0·0%) 
DXA Hologic QDR 4500, (Hologic, 
Bedford, MA, USA) 
Total hip, femoral 





TSH ≥4·5mIU/l & TSH 
<20mIU/l, normal fT4 0·7-
1·8ng/dl (9-23pmol/l) or 
missing fT4 (0/4, 0·0%) 
TSH <0·45mIU/l & normal fT4 
0·7-1·8ng/dl (9-23pmol/l) or 
missing fT4 (0/102, 0·0%) 
DXA Hologic QDR 4500, (Hologic, 
Bedford, MA, USA/ Lunar 
Expert XL (GE Lunar Corp., 
Madison, WI) 
Total hip, femoral 
neck, lumbar spine  
Rotterdam 
Study (34)  
TSH ≥4·5mIU/l & TSH 
<20mIU/l, normal fT4 0·9-
1·9ng/dl (11-25pmol/l) or 
missing fT4 (29/84, 34·5%) 
TSH <0·45mIU/l & normal fT4 
0·9-1·9ng/dl (11-25pmol/l) or 
missing fT4 (22/101, 21·8%) 
DXA Lunar DPX, (Madison, WI, 
USA) 
 




TSH ≥4·5mIU/l & TSH 
<20mIU/l, normal fT4 0·9-
1·7ng/dl (12-22pmol/l) or 
missing fT4 (0/16, 0·0%) 
TSH < 0·45mIU/l & normal fT4 
0·9-1·7ng/dl (12-22pmol/l) or 
missing fT4 (0/4, 0·0%) 
DXA Lunar DPX, (Madison, WI, 
USA) 
 
Total hip, femoral 
neck, lumbar spine  
 
Legend:  *  For a better comparability, we used a homogenous definition of TSH ranges based on an expert consensus meeting of the Thyroid Studies Collaboration (International Thyroid 
Conference, Paris, 2010), Individual free thyroxine (fT4) cut-off values for each cohort. based on an expert consensus meeting of the Thyroid Studies Collaboration (International Thyroid 
Conference, Paris, 2010), All BMD values were analyzed in g/cm2. Abbreviations: BMD: bone mineral density; DXA: dual x-ray absorptiometry; fT4: free thyroxine; L: lumbar vertebra; TSH: 
thyroid-stimulating hormone.  † fT4 was measured only in participants with TSH ≤ 0.10mIU/l or TSH ≥ 7.00mIU/l  
24 
 











Assessment of relevant co-
medication at baseline 

























Anti-osteoporotic medication, oral 
corticosteroids, hormone replacement 
therapy, proton pump inhibitors, 
thyroxine, antithyroid medication, 
lithium, amiodarone 
Regular cross-calibration of 
devices/sites with anthropometric 
phantoms. Regular longitudinal 
change calibration with phantom 
59·2% § 6 
4·0 
(4·0-4·0) 













Anti-osteoporotic medication, oral 
corticosteroids, hormone replacement 
therapy, thyroxine, antithyroid 
medication, lithium, amiodarone 
Regular cross-calibration of 
devices/sites with anthropometric 
spine phantoms. Longitudinal 













Age, sex, BMI, 
diabetes mellitus, 
smoking status, 
Anti-osteoporotic medication, oral 
corticosteroids, proton pump inhibitors, 
androgens, thyroxine, antithyroid 
medication, lithium, amiodarone 
Regular cross-calibration of 
devices/sites, and calibration for 
















Anti-osteoporotic medication, oral 
corticosteroids, hormone replacement 
therapy, proton pump inhibitors, 
thyroxine 
Regular cross-calibration of 
devices/sites, and calibration for 
longitudinal changes using 














Anti-osteoporotic medication, oral 
corticosteroids, hormone replacement 
therapy, proton pump inhibitors, 
thyroxine, antithyroid medication, 
lithium, amiodarone 
Cross calibration of devices by 
performing repeated measurements 














Anti-osteoporotic medication, oral 
corticosteroids, hormone replacement 
therapy, thyroxine 
Cross-calibration of devices, and 
calibration for longitudinal changes 







Abbreviations: BMD: bone mineral density at any site of interest (femoral neck, total hip, lumbar spine); BMI: body mass index; DXA: dual x-ray absorptiometry; IQR: interquartile range; TSH: thyroid-stimulating 
hormone; 
* Blinding of participants, treating physicians, study nurses and investigators involved in BMD measurements and fracture adjudication. 
† no serial measurements of bone mineral density at the femoral neck, total hip and lumbar spine region at any point during follow-up.  
‡ Quality assessment using a slightly modified Newcastle-Ottawa Quality Assessment Scale –Cohort Studies (13) including following criteria (1 point each): “Representativeness of the exposed cohort”, “Selection 
of the non-exposed cohort”, “Ascertainment of exposure”, “Comparability of cohorts on the basis of the design or analysis”, “Assessment of outcome”, “Was follow-up long enough for outcomes to occur”, 
“Adequacy of follow-up of cohorts”. The criterion “Demonstration that outcome of interest was not present at start of study” could not be considered as bone loss is a continuous outcome. Therefore, a maximum 
score of 7 points can be achieved. 




Appendix Table 3: Sensitivity Analyses for the Multivariable-Adjusted* Association between 




%ΔBMD 95% CI I2 p  
Femoral Neck      
Main analysis:                                                         
Exclusion of bone drug users† at baseline 
448/4700 0·00 -0·12; 0·13 0·0% 0·52 
and no history of osteoporosis, and/or 
previous, and/or incident fractures 
327/3517 -0·03 -0·17; 0·12 0·0% 0·47 
Exclusion of bone drug users at any time 330/3559 0·08 -0·06; 0·23 0·0% 0·50 
Exclusion of both thyroid‡- and bone-
influencing drug users at any time 
222/3348 0·08 -0·10; 0·27 1·9% 0·40 
Exclusion of cohorts with >20% missing 
follow-up BMD § 
326/2968 0·01 -0·15; 0·17 0·0% 0·59 
Total Hip      
Main analysis:                                                         
Exclusion of bone drug users† at baseline 
411/4122 0·02 -0·08; 0·12 0·0% 0·48 
and no history of osteoporosis, and/or 
previous, and/or incident fractures 
295/3013 -0·01 -0·12; 0·11 0·0% 0·52 
Exclusion of bone drug users at any time 295/3037 0·10 -0·02; 0·22 0·0% 0·78 
Exclusion of both thyroid‡- and bone-
influencing drug users at any time 
192/2844 0·14 -0·01; 0·28 0·0% 0·76 
Exclusion of cohorts with >20% missing 
follow-up BMD § 
288/2389 0·05 -0·09; 0·19 0·0% 0·98 
Lumbar Spine      
Main analysis:                                                         
Exclusion of bone drug users† at baseline 
323/2974 -0·01 -0·34; 0·32 37·7% 0·19 
and no history of osteoporosis, and/or 
previous, and/or incident fractures 
216/1985 -0·10 -0·34; 0·14 0·0% 0·70 
Exclusion of bone drug users at any time 220/2069 -0·08 -0·34; 0·18 0·0% 0·82 
Exclusion of both thyroid‡- and bone-
influencing drug users at any time 
141/1930 -0·11 -0·43; 0·21 0·0% 0·80 
Exclusion of cohorts with >20% missing 
follow-up BMD § 
243/1619 -0·08 -0·31; 0·15 0·0% 0·54 
 
Footnote: Abbreviations: %ΔBMD: annualized percentage change in bone mineral density compared to euthyroid individuals, I2: I2 
statistics, 95%CI: 95% confidence intervals; N: number of participants; p = p for heterogeneity; SHypo: subclinical hypothyroidism. 
* Multivariable adjustment for age, gender, body mass index, smoking and menopausal status, history of diabetes. Values presented as mean 
difference in annualized percentage change in BMD, as compared to euthyroid controls. 
† Bone drug users with intake of either bisphosphonates, calcitonin, teriparatide, selective estrogen receptor modulators, oral corticosteroids, 
thiazide diuretics, androgens, anti-androgens, hormone replacement therapy or proton pump inhibitors.  
‡ Thyroid-altering drug users with intake of either thyroxine, antithyroid drugs, amiodarone, or lithium. 
§ Exclusion of the Cardiovascular Health Study,(35) Osteoporotic Fractures in Men (MrOS) Study,(10) and Osteoporosis and Ultrasound 
Study (OPUS)(36) for the sensitivity analysis of  %ΔBMD at the femoral neck and total hip. Additionally, no data available for %ΔBMD at 
the lumbar spine in Rotterdam Study.(34)
27 
 
Appendix Table 4: Secondary Analyses on the Association between Annualized Percentage 
Change in Bone Mineral Density (BMD) as a Continuous Variable and Fracture Risk and Effect 
Modification by Thyroid Status (SHyper vs. Euthyroidism) 
 
 
Footnote:  Abbreviations: BMD: bone mineral density; %ΔBMD: annualized percentage change in bone mineral density 
compared to euthyroid individuals, HR: hazard ratio, SHyper: subclinical hyperthyroidism, 95%CI: 95% confidence interval. 
* Hip fractures comprise pertrochanteric, subtrochanteric and femoral neck fractures. Exclusion of periprosthetic and pathologic fractures in this 
region 
† Any fractures comprise both non-spine and radiologically confirmed spine fractures. The Cardiovascular Health Study could not 
contribute due to missing information on spine and non-spine fractures other than hip fractures.  
‡ Incident non-spine fractures defined as hip or any other non-pathologic fractures excluding the spinal, cranial/facial and acral 
fractures. The Cardiovascular Health Study, Sheffield and Osteoporosis and Ultrasound (OPUS) studies could not contribute due 
to missing assessment of any fractures. 
§ Multivariable adjustment for age, gender, body mass index, history of diabetes mellitus and smoking status 
  %ΔBMD femoral neck 





 HR 95%CI 
p for 
interaction 
Hip fractures *             
adjusting for age and gender        
SHyper 1·08 0·80-1·47 
0·24 
 1·21 0·77-1·89 
0·07 
Euthyroidism 0·90 0·83-0·97  0·79 0·71-0·88 
multivariable adjustment §        
SHyper 1·08 0·80-1·46 
0·27 
 1·12 0·72-1·74 
0·13 
Euthyroidism 0·91 0·84-0·98   0·79 0·71-0·89 
Any fractures †        
adjusting for age and gender        
SHyper 0·94 0·80-1·10 
0·60 
 0·88 0·74-1·04 
0·57 
Euthyroidism 0·90 0·85-0·94  0·83 0·77-0·90 
multivariable adjustment §        
SHyper 0·94 0·81-1·10 
0·56 
 0·88 0·75-1·04 
0·58 
Euthyroidism 0·90 0·86-0·94   0·84 0·77-0·90 
Non-spine fractures        
adjusting for age and gender        
SHyper 0·93 0·78-1·10 
0·85 
 0·89 0·74-1·09 
0·80 
Euthyroidism 0·94 0·90-0·99  0·92 0·85-1·00 
multivariable adjustment §     
  
 
SHyper 0·94 0·79-1·11 
0·87 
 0·90 0·75-1·09 
0·86 
Euthyroidism 0·95 0·90-1·00  0·92 0·85-1·00 
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Records + prospective 
cohort studies assessed for 
eligibility  
(n = 9 + 8) 
Potentially eligible studies, but not 
comparable to others since no dual x-ray 
absorptiometry and no measurement of one 
mineral density at femoral neck, total hip, 
lumbar spine. (n = 2) 
 
One published record from included cohort 
study by contact with experts and members 
of the Thyroid Studies Collaboration (n = 1) 
Prospective cohort studies 
providing IPD included in 
main analysis                           
(n = 6 ) 
Records + prospective 
cohort studies meeting 
eligibility criteria                    
(n = 1 + 8) 
Full-text articles excluded due to 
 Review article, meeting abstract, 
poster or editorial without access to 
IPD (n = 4) 
 No fT4 measurement (n = 2) 
 No serial BMD measurements (n = 1) 
 No euthyroid control group (n = 1) 
 
Records excluded based on title and abstract  
(unrelated to the association between 
subclinical thyroid dysfunction 
and serial BMD measurements, or no 
prospective study with thyroid measurement) 
(n = 1398) 
Records + prospective 
cohort studies after removal 
of duplicates  
(n = 1407 + 8) 
Legend: BMD: bone mineral density, fT4: free thyroxine, IPD: individual participant data, n= number of studies 
Records identified through 
database searching 
(MEDLINE/EMBASE)           
(n =1558)              
 
Contact with experts & 
members of the Thyroid 
Studies Collaboration/ (n=8).  
 
 
Duplicates removed (n=151) 
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Appendix Figure 2: Subclinical Hyperthyroidism and Annualized Percentage Change in Femoral Neck Bone Mineral Density Compared to Euthyroid 
Individuals 
 
Legend: Multivariable adjustment for age, sex, bone mass index, smoking and menopausal status, history of diabetes. Values presented as mean difference in annualized percentage change in BMD 




Details of statistical approach 
Considering the effects of bone- and thyroid-altering medication on BMD, we conducted the 
main analysis on individuals without bone-altering medication at baseline, and provided 
sensitivity analyses with 1) additional exclusion of participants with history of osteoporosis, 
and previous or incident hip, spine, or non-spine fractures during observation time, 2) bone-
altering medication at any time (i.e. at baseline and/or follow-up visits), 3) exclusion of both 
thyroid- and bone-altering drug users at any time, 4) exclusion of cohorts with >20% missing 
follow-up BMD for %ΔBMD at any site (Appendix Table 2), and 5) selection of participants 
with SHyper and TSH<0·10 mUI/l in order to investigate those with suppressed TSH levels. 
Similar to previous IPD analyses,(7, 14) we performed stratified analyses for sex, age, and 
cohort-specific fT4 quartiles using the same multivariate regression models as explained above. 
When investigating %ΔBMD as a potential mediator in the association between SHyper and 
fractures, we used the same sample as for the main analysis, and conducted a one-step approach 
analysis, using a multivariable shared frailty Cox proportional hazards model controlling for 
the same covariates (age, sex, BMI, smoking status) as in Blum et al..(7) We added %ΔBMD 
and baseline BMD at the total hip as new covariates to the multivariable model in order to 
assess changes in risk estimates. Additionally, we assessed the association between %ΔBMD 
at the femoral neck/total hip (as a continuous variable), and fractures using a multivariable Cox 
regression model adjusting for 1) age and gender, 2) age, gender plus BMI, smoking status and 
diabetes mellitus). We then stratified the analysis according to thyroid status (SHyper vs. 
euthyroidism) in order to examine a potential effect modification by thyroid status. 
 
 
